Careteq Ltd. (AU:CTQ)
ASX:CTQ
Want to see AU:CTQ full AI Analyst Report?
Top Page
Careteq Ltd.
(Sydney:CTQ)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.02
▲(50.00% Upside)
Action:Reiterated
Date:06/16/26
The score is held back primarily by weak financial resilience—higher leverage and persistently negative operating/free cash flow—despite meaningful improvement toward break-even profitability. Technicals are supportive with price above major moving averages and a positive MACD, but extreme overbought signals (RSI 100) add short-term risk. Valuation remains constrained by negative earnings and no dividend data.
Positive Factors
Revenue Scale-up
Material multi-year revenue growth demonstrates product-market fit and successful commercialisation of assistive healthcare offerings. A larger revenue base improves the company's ability to invest in R&D, sales channels and supports longer-term operating leverage as fixed costs are spread.
Negative Factors
Rising Leverage
A sharp increase in leverage materially reduces financial flexibility and raises refinancing and interest coverage risk. If profitability or cash conversion falter, higher debt magnifies downside and could force dilutive financing or constrain strategic investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scale-up
Material multi-year revenue growth demonstrates product-market fit and successful commercialisation of assistive healthcare offerings. A larger revenue base improves the company's ability to invest in R&D, sales channels and supports longer-term operating leverage as fixed costs are spread.
Read all positive factors
Careteq Ltd. (CTQ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$9.53M
Dividend YieldN/A
Average Volume (3M)84.31K
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue Growth-48.09%
EPS Growth87.88%
CountryAU
Employees686
SectorHealthcare
Sector Strength45
IndustrySpecialty Business Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding733,118,700
10 Day Avg. Volume0
30 Day Avg. Volume84,309
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)2.61
Price to Sales (P/S)0.52
P/FCF Ratio-4.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Careteq Ltd. Business Overview & Revenue Model
Company Description
Careteq Limited engages in medication management and clinical governance for health, aged, and home care sectors in Australia. The company provides healthcare safety and clinical services. Careteq Limited was incorporated in 2016 and is based in M...
How the Company Makes Money
Careteq Ltd. generates revenue primarily through the sale of its healthcare technology solutions, including smart assistive devices, subscriptions for cloud-based health monitoring services, and licensing agreements. Additional revenue streams may...
Careteq Ltd. Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
35
Negative
Cash Flow
28
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.67M | 7.62M | 7.23M | 4.98M | 4.43M | 735.44K |
| Gross Profit | 645.22K | 1.50M | 6.74M | -2.44M | 4.14M | -2.03M |
| EBITDA | -614.76K | 275.62K | -826.62K | -2.65M | -5.90M | -5.06M |
| Net Income | -199.98K | -72.20K | -2.67M | -4.33M | -5.25M | -5.23M |
Balance Sheet | ||||||
| Total Assets | 4.44M | 5.94M | 6.82M | 7.57M | 8.02M | 12.23M |
| Cash, Cash Equivalents and Short-Term Investments | 681.80K | 1.05M | 1.25M | 1.85M | 4.50M | 8.90M |
| Total Debt | 2.30M | 2.37M | 192.98K | 961.96K | 0.00 | 75.28K |
| Total Liabilities | 3.20M | 4.42M | 3.30M | 4.02M | 1.72M | 2.61M |
| Stockholders Equity | 1.24M | 1.52M | 1.97M | 2.14M | 6.30M | 9.61M |
Cash Flow | ||||||
| Free Cash Flow | -624.11K | -804.93K | -2.59M | -3.42M | -4.54M | -1.52M |
| Operating Cash Flow | -546.57K | -732.06K | -1.30M | -2.53M | -4.52M | -1.50M |
| Investing Cash Flow | -180.51K | 119.16K | -570.80K | -799.63K | -256.83K | -23.21K |
| Financing Cash Flow | 537.96K | 400.96K | 1.27M | 687.55K | 8.81M | 1.50M |
Careteq Ltd. Technical Analysis
Negative
0.01
Price Trends
0.01
Negative
0.01
Negative
0.01
Negative
Market Momentum
>-0.01
Positive
46.30
Neutral
-44.44
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CTQ, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.30 is Neutral, neither overbought nor oversold. The STOCH value of -44.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CTQ.
Careteq Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$9.53M | -14.44 | -14.47% | ― | -48.09% | 87.88% | |
44 Neutral | AU$20.90M | -2.85 | -1009.84% | ― | 13.69% | 7.57% | |
43 Neutral | AU$15.74M | ― | -578.72% | ― | 43.55% | 26.03% | |
42 Neutral | AU$57.82M | -7.69 | -59.96% | ― | ― | ― | |
41 Neutral | AU$3.47M | 63.50 | 15.41% | ― | -5.76% | 8.00% |
* Healthcare Sector Average
AU:CTQ
Careteq Ltd.
0.01
<0.01
18.18%
AU:GLH
Global Health Limited
0.06
>-0.01
-13.24%
AU:SHG
Singular Health Group Ltd
0.18
-0.19
-51.35%
AU:ICR
InteliCare Holdings Limited
0.02
<0.01
57.14%
AU:PCK
PainChek Ltd
0.10
-0.35
-77.78%
Careteq Ltd. Corporate Events
Careteq Issues 35.6 Million New Shares in Routine Capital Management Move
Jun 3, 2026
Careteq Limited has issued 35,567,808 fully paid ordinary shares at $0.01 per share, expanding its share base via a placement conducted without a prospectus under the Corporations Act. The company confirmed it is compliant with its financial repor...
Careteq clears debt as Tony G converts notes into equity
Jun 3, 2026
Careteq Limited has strengthened its capital structure after strategic investor Antanas Guoga, a prominent European technology investor and former Member of the European Parliament, converted 355,678 unquoted convertible notes into 35,567,808 full...
Careteq adds seasoned director Leonard Math to board as it pursues AI healthtech growth
Jun 3, 2026
Careteq Limited has strengthened its board with the appointment of experienced company director and Chartered Accountant Leonard Math as a Non-Executive Director, effective immediately. Math brings more than 18 years of experience across ASX-liste...
Careteq Corrects Q3 Report to Disclose $113k in Related-Party Payments
May 5, 2026
Careteq Limited has corrected its Q3 FY26 quarterly activities report after omitting required disclosure on payments to related parties. The company clarified that these payments totalled $113,000 and comprised director fees, salaries and superann...
Careteq Issues 50 Million Unlisted Options to Expand Capital Flexibility
May 4, 2026
Careteq Ltd. has notified the market of the issue of 50 million unlisted options, which are unquoted equity securities not intended to trade on the ASX. The options, recorded under a new class code yet to be confirmed, were issued on 5 May 2026 as...
Careteq Issues 401 Million New Shares to Strengthen Capital Base
May 4, 2026
Careteq Limited has issued 401,367,364 new fully paid ordinary shares at $0.005 per share, expanding its capital base through a placement conducted without a disclosure document under specific provisions of the Corporations Act. The company confir...
Careteq Seeks ASX Quotation for Over 401 Million New Shares
May 4, 2026
Careteq Ltd. has applied for quotation on the ASX of 401,367,364 ordinary fully paid shares under its CTQ ticker, with an issue date of 5 May 2026. The large volume of new quoted securities, issued as part of previously announced transactions, ind...
Careteq Turns Cash-Flow Positive as It Sells EHS and Doubles Down on HMR Referrals
Apr 30, 2026
Careteq reported a solid March quarter with customer receipts of $2.2 million and a return to positive operating cash flow, alongside an increase in quarter-end cash to $837,000. The company also completed a $2.2 million two-tranche equity placeme...
Careteq Secures Full Shareholder Backing as All General Meeting Resolutions Pass
Apr 23, 2026
Careteq Limited has confirmed that all resolutions put to shareholders at its general meeting held on 23 April 2026 were passed. The approval of every resolution signals solid shareholder support for the company’s current strategy and govern...
Careteq Completes Sale of Embedded Health Unit to Fund Platform Growth and Strengthen Balance Sheet
Apr 8, 2026
Careteq Limited has completed the sale of its wholly owned subsidiary Embedded Health Solutions to Nationwide Investments Holdings for $5 million, subject to customary adjustments of about $990,000 for working capital and employee entitlements. A ...
Careteq Sets Fully Virtual General Meeting for April 2026
Mar 24, 2026
Careteq Limited has called a virtual general meeting of shareholders for 23 April 2026, instructing investors on how to participate and vote online via the Automic platform. The company is emphasizing early proxy lodgement, electronic communicatio...
Careteq Raises New Equity Through Share Issue at $0.005
Mar 18, 2026
Careteq Limited has issued 38,632,636 fully paid ordinary shares at $0.005 per share, expanding its share capital via a placement conducted without a disclosure document under the Corporations Act. The company confirmed it is compliant with its fi...
Careteq Seeks ASX Quotation for 38.6 Million New Shares
Mar 18, 2026
Careteq Ltd. has applied to the Australian Securities Exchange for quotation of 38,632,636 ordinary fully paid shares, with an issue date of 19 March 2026. The new securities, linked to transactions previously flagged to the market, will expand th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.